TABLE 1.
Co‐delivery of resveratrol nano‐formulations with various chemotherapy drugs
| Nanocarrier system | Co‐delivery drug combination | Cancer | Important findings |
|---|---|---|---|
| Pegylated nanoliposomes 80 | Resveratrol and 5‐fluorouracil | Head and neck squamous cell carcinoma | Co‐encapsulation of drugs showed different effects on different genes and enhanced the cytotoxicity in comparison to free drug drugs |
| Shell crosslinked zein nanocapsules 12 | Exemestane and resveratrol | Breast cancer | Nanocapsules enhanced the cytotoxicity against MCF‐7 and 4 T1 breast cancer cells and reduced the tumor volume by 2.4‐fold compared to the free drug combination |
| Folic acid conjugated nanoparticles 13 | Resveratrol and docetaxel | Prostate cancer | Nanoparticles downregulated the expression of NF‐kB p65, cox‐2, and antiapoptotic genes and exhibited additional cytotoxic effects with the downregulation of survivin and upregulation of cleaved caspase‐3 |
| Co‐encapsulated liposomes 81 | Resveratrol and paclitaxel | Breast cancer | Composite liposomes showed improved cytotoxicity against drug‐resistant MCF‐7/Adr tumor cells in vitro and enhanced the tumor retention of drugs in vivo. |
| Alginate nanoparticles 82 | Curcumin and resveratrol | Prostate cancer | Curcumin was found to have good cellular uptake from both the solution as well as nanoparticles. Whereas resveratrol showed poor cellular uptake. |
| Epidermal growth factor conjugated lipid‐polymer hybrid nanoparticles 14 | Docetaxel and resveratrol | Non‐small cell lung cancer | Nanoparticle co‐delivery system showed significant synergistic effect and tumor growth inhibition with lowest systemic toxicity for both in vitro and in vivo studies. |
| Solid lipid nanoparticles 83 | Curcumin and resveratrol as a complex with gelucire | Colon cancer | Curcumin‐resveratrol‐gelucire (CRG) complex showed better IC50 value than CRG‐cyclodextrin complex |
| Phytosomal bilayer enveloped casein micelles 84 | Monascus yellow pigments and resveratrol | Breast cancer | Multireservoir nanocarrier system showed superior cell cytotoxicity, reduction of tumor volume, and inhibition of tumor growth biomarkers |
| Lactobionic/folate dual‐targeted amphiphilc maltodextrin‐based micelles 85 | Sulfasalazine and resveratrol | Liver cancer | The dual‐targeted micelles showed enhanced cytotoxicity and internalization, reduced liver/body weight ratio, inhibition of angiogenesis, and enhanced apoptosis |
| Polymeric nanocarriers 86 | Resveratrol and docetaxel | Breast cancer | Polymeric micelles exhibited prolonged release profiles and improved anticancer effect compared to individual drugs in vitro |
| Polymeric micelles 87 | Resveratrol and curcumin co‐administered with doxorubicin | Ovarian cancer | Coadministration mitigated the doxorubicin induced cardiotoxicity by reduction of apoptosis and ROS and improved the potency of doxorubicin in ovarian cancer cells |
| Novel peptide‐cationic liposomal nanocarrier 88 | Resveratrol and P53 gene | Cervical cancer and breast cancer | Co‐delivery system showed greater tumor inhibition and apoptosis‐inducing activity than resveratrol liposomes or p53 gene liposomes |
| Ultradeformable liposomes 89 | Resveratrol and 5‐fluorouracil | Non‐melanoma skin cancer | Co‐encapsulation in ultra‐deformable liposomes showed higher anticancer activity and enhanced accumulation in the deeper skin layers compared to both the free drugs and single entrapped agents |
| Cyclodextrin nanosponge based hydrogel 90 | Resveratrol and curcumin | Breast cancer | Drug loaded nanosponges showed enhanced in vitro release of curcumin and resveratrol by 10 and 2.5‐fold respectively and higher cytotoxicity compared to free drug |
| Mesoporous silica nanoparticles 91 | Anti‐miR21 and resveratrol | Colon cancer | The nanoparticles containing hyaluronic acid/resveratrol and antimiR21 showed 3‐fold higher tumor regression effect compared to free resveratrol and 2‐fold higher tumor regression compared to resveratrol‐miR21 nanoparticles |
| Self‐microemulsifying system 92 | Curcumin and resveratrol | Colon cancer | Co‐formulation showed greater antioxidant activity and lower cytotoxicity than the formulation with individual compounds |
| Lyotropic liquid crystalline nanoparticles 93 | Resveratrol and pemetrexed | Non‐small cell lung cancer | The nanoparticles showed superior cytotoxicity profile with enhanced cellular uptake and tumor growth inhibition via inhibition of angiogenesis and induction of apoptosis |
| Polymeric micelles 94 | Co‐delivery of quercetin/resveratrol and resveratrol/curcumin | Ovarian cancer | Micellar formulations of resveratrol and curcumin co‐administered with Adriamycin showed significant tumor reduction and thus capable of mitigating Adriamycin induced cardiotoxicity |